Cellectis to Report Third Quarter Financial Results on November 7, 2025

Core Points - Cellectis, a clinical-stage biotechnology company, will report its financial results for Q3 2025 on November 7, 2025, after the US market closes [1] - The company specializes in gene-editing technology to develop cell and gene therapies, particularly focusing on CAR T immunotherapies for oncology [2][3] Company Overview - Cellectis employs an allogeneic approach for CAR T immunotherapies, aiming to create off-the-shelf, ready-to-use gene-edited CAR T-cells for cancer treatment [2] - The company has in-house manufacturing capabilities, making it one of the few end-to-end gene editing companies that manage the entire cell and gene therapy value chain [2] - Cellectis is headquartered in Paris, France, with additional locations in New York and Raleigh, NC, and is listed on both Nasdaq (ticker: CLLS) and Euronext Growth (ticker: ALCLS) [2]